Aberdeen Group plc Increases Stock Holdings in Sera Prognostics, Inc. $SERA

Key Points

• Aberdeen Group plc increased its holdings in Sera Prognostics by 79.6%, acquiring an additional 987,367 shares to own 5.91% of the company, valued at approximately $6.17 million.
• Sera Prognostics reported an earnings per share (EPS) of ($0.16), exceeding analysts' expectations of ($0.21), but generated only $0.02 million in revenue against a forecast of $0.05 million.
• Several analysts have downgraded Sera Prognostics' stock, with Weiss Ratings reiterating a "sell" rating and Wall Street Zen lowering their rating from "hold" to "sell".

Aberdeen Group plc grew its position in Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) by 79.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,227,367 shares of the company's stock after buying an additional 987,367 shares during the quarter. Aberdeen Group plc owned 5.91% of Sera Prognostics worth $6,170,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. XTX Topco Ltd purchased a new position in shares of Sera Prognostics in the first quarter valued at $39,000. Abel Hall LLC purchased a new position in shares of Sera Prognostics in the second quarter valued at $31,000. Wagner Wealth Management LLC purchased a new position in shares of Sera Prognostics in the second quarter valued at $34,000. Nuveen LLC purchased a new stake in Sera Prognostics during the 1st quarter worth about $138,000. Finally, Rhumbline Advisers increased its position in Sera Prognostics by 10.7% during the 1st quarter. Rhumbline Advisers now owns 39,970 shares of the company's stock worth $147,000 after purchasing an additional 3,869 shares in the last quarter. Hedge funds and other institutional investors own 54.64% of the company's stock.

Sera Prognostics Trading Up 6.7%

Sera Prognostics stock opened at $3.34 on Friday. The stock has a 50-day moving average price of $2.96 and a 200 day moving average price of $2.71. Sera Prognostics, Inc. has a 52 week low of $1.37 and a 52 week high of $9.13. The stock has a market cap of $125.82 million, a PE ratio of -3.93 and a beta of 0.97.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%.The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. On average, equities analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Insider Transactions at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 21,158 shares of the firm's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $3.15, for a total value of $66,647.70. Following the sale, the chief executive officer directly owned 811,136 shares of the company's stock, valued at approximately $2,555,078.40. This trade represents a 2.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders sold 50,631 shares of company stock valued at $153,604. 13.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently commented on SERA shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Sera Prognostics in a research report on Wednesday, October 8th. Wall Street Zen cut Sera Prognostics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of "Sell".

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

Want to see what other hedge funds are holding SERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sera Prognostics, Inc. (NASDAQ:SERA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.